MarketPulse
T

$TLX

4 articles found
4 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Telix Pharmaceuticals Limited

Telix Resubmits FDA Application for Brain Cancer Imaging Drug Pixclara

Telix resubmits FDA application for Pixclara, a brain cancer imaging agent with Orphan Drug and Fast Track designations, addressing a regulatory Complete Response Letter.
TLXorphan drug designationradiopharmaceuticals
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Telix Pharma's TLX591-Tx Clears Phase 3 Safety Hurdle, Paves Path to Expansion

Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.
TLXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Telix Pharmaceuticals Hosts Major PSMA Imaging Webinar as Prostate Cancer Focus Sharpens

Telix Pharmaceuticals announces March 2026 webinar on PSMA-PET/CT imaging innovations, featuring leading oncology experts discussing prostate cancer detection advances.
TLXradiopharmaceuticalsinvestor relations
The Motley FoolThe Motley Fool··James Halley

Telix Pharmaceuticals Eyes Growth With Nuclear Medicine Expansion

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.
TLXbiotechradiopharmaceuticals